Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Equity Income (2018 - 2022)

Arcturus Therapeutics Holdings' Equity Income history spans 5 years, with the latest figure at -$131000.0 for Q2 2022.

  • For Q2 2022, Equity Income rose 60.06% year-over-year to -$131000.0; the TTM value through Dec 2022 reached -$515000.0, down 200.0%, while the annual FY2022 figure was -$515000.0, 200.0% down from the prior year.
  • Equity Income reached -$131000.0 in Q2 2022 per ARCT's latest filing, up from -$384000.0 in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $1.2 million in Q1 2021 to a low of -$384000.0 in Q1 2022.
  • Average Equity Income over 5 years is -$46000.0, with a median of -$143000.0 recorded in 2021.
  • The largest YoY upside for Equity Income was 865.64% in 2021 against a maximum downside of 228.0% in 2021.
  • A 5-year view of Equity Income shows it stood at -$255000.0 in 2018, then surged by 81.57% to -$47000.0 in 2019, then crashed by 112.77% to -$100000.0 in 2020, then plummeted by 55.0% to -$155000.0 in 2021, then grew by 15.48% to -$131000.0 in 2022.
  • Per Business Quant, the three most recent readings for ARCT's Equity Income are -$131000.0 (Q2 2022), -$384000.0 (Q1 2022), and -$155000.0 (Q4 2021).